Compare Weibo Corp (WB) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Weibo Corp vs Zimmer Biomet Holdings Inc — how do they compare? Weibo Corp trades at $6.64 (market cap $1.64B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 11× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (9.11%). Which is the better fit depends on your goals.
| WB | ZBH | |
|---|---|---|
Market Cap | $1.64B | $17.97B |
Sector | Media | Health |
52-Week High | $12.83 | $104.26 |
52-Week Low | $6.63 | $79.58 |
Enterprise Value | $866.57M | $25.04B |
Dividend Yield | 9.11% | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Weibo (WB) trades at $6.70, down 0.3% on the day, with mixed technical signals showing bearish moving averages but bullish oscillators. Fundamentally, the stock appears undervalued with a P/E of 5.53 and P/B of 0.41, while maintaining strong profitability with 73.36% gross margins and 17.78% net income margin. Recent Q2 2026 earnings beat expectations with $0.38 EPS versus $0.36 expected, though Q1 and Q4 2025 missed estimates.
The investment case balances deep value metrics against structural challenges. While the stock trades below book value and generates substantial cash flow, competitive pressures from Douyin and WeChat threaten long-term relevance. Analyst sentiment is divided with 41% buy ratings but 45% holds, reflecting uncertainty about growth visibility amid declining user metrics. The 8% dividend yield provides downside protection but may not offset fundamental erosion risks.
Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.
The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
